{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:33:16Z","timestamp":1789907596057,"version":"4.0.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clml.2024.01.014","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T21:05:42Z","timestamp":1706821542000},"page":"e217-e225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.01.014_sbref0001","year":"2021"},{"key":"10.1016\/j.clml.2024.01.014_sbref0002","year":"2023"},{"issue":"8","key":"10.1016\/j.clml.2024.01.014_bib0003","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.clml.2024.01.014_bib0004","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2024.01.014_bib0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0006","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.01.014_bib0007","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.01.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncology Practice"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0010","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41409-022-01905-1","article-title":"Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy","volume":"58","author":"Al Hadidi","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2024.01.014_bib0011","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"8","key":"10.1016\/j.clml.2024.01.014_bib0012","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2024.01.014_bib0013","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clml.2022.09.001","article-title":"Recent advances in the use of chimeric antigen receptor-expressing T-cell therapies for treatment of multiple myeloma","volume":"23","author":"Martin","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0014","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.01.014_bib0015","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03601078. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0016","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04196491. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0017","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04855136. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0018","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04133636. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0019","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04181827. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0020","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04923893. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0021","unstructured":"National Institutes of Health, US National Library of Medicine. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05257083. 2023. Accessed: January 15, 2024."},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0022","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clml.2024.01.014_bib0023","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0024","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.01.014_bib0025","first-page":"27","article-title":"Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings","volume":"23","author":"Beaupierre","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clml.2024.01.014_bib0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-017-0239-0","article-title":"The why, what, and how of the new FACT standards for immune effector cells","volume":"5","author":"Maus","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clml.2024.01.014_bib0027","series-title":"Standards for Immune Effector Cells, First Edition 1.1","year":"2018"},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0028","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1001\/jamaoncol.2022.6834","article-title":"Chimeric antigen receptor T-cell therapy for patients with multiple myeloma: a call for equal opportunity","volume":"9","author":"Goldfinger","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.01.014_bib0029","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.01.014_bib0030","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"11","key":"10.1016\/j.clml.2024.01.014_bib0031","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.01.014_bib0032","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.01.014_bib0033","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2022-166454","article-title":"Advancing CAR T-cell care in relapsed\/refractory multiple myeloma: insights from a collaborative quality improvement initiative","volume":"140","author":"Ailawadhi","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.01.014_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.01.014_bib0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000528331","article-title":"Get off on the right foot: how to plan an efficient leukocytapheresis to collect T cells for CAR T-cell manufacturing","volume":"50","author":"Pineyroa","year":"2023","journal-title":"Transfus Med Hemother"},{"issue":"1","key":"10.1016\/j.clml.2024.01.014_bib0036","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0037","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"27","key":"10.1016\/j.clml.2024.01.014_bib0038","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.01.014_bib0039","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"CAR T-cell therapy for myeloma: where are we now and what is needed to move CAR T-cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2024.01.014_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.780442","article-title":"T cell fitness and autologous CAR T cell therapy in haematologic malignancy","volume":"12","author":"Mehta","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0041","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s40883-019-00124-3","article-title":"The challenge of variability in chimeric antigen receptor T cell manufacturing","volume":"6","author":"Fesnak","year":"2020","journal-title":"Regen Eng Transl Med"},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0042","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"issue":"19","key":"10.1016\/j.clml.2024.01.014_bib0043","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.01.014_bib0044","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.014_bib0045","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1182\/blood-2022-169783","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"140","author":"Iacoboni","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.014_bib0046","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","article-title":"Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T cells","volume":"11","author":"Cooke","year":"2020","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.clml.2024.01.014_bib0047","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1002\/cncr.29533","article-title":"A comparison of salvage infusional chemotherapy regimens for recurrent\/refractory multiple myeloma","volume":"121","author":"Griffin","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2024.01.014_bib0048","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.18609\/cgti.2018.105","article-title":"Management of \u2018out of specification\u2019 commercial autologous CAR-T cell products","volume":"4","author":"Bersenev","year":"2018","journal-title":"Cell Gene Therapy Insights"},{"issue":"21","key":"10.1016\/j.clml.2024.01.014_bib0049","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2024.01.014_bib0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.01.014_bib0051","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-143336","article-title":"Factors affecting lymphocyte collection efficiency and manufactured product specification during leukapheresis for diffuse large B cell lymphoma patients treated with commercial tisagenlecleucel","volume":"136","author":"Perez Perez","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.014_bib0052","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1002\/acg2.75","article-title":"Important aspects of T-cell collection by apheresis for manufacturing chimeric antigen receptor T cells","volume":"3","author":"Paroder","year":"2020","journal-title":"Adv Cell Gene Therapy"},{"issue":"2","key":"10.1016\/j.clml.2024.01.014_bib0053","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.01.014_bib0054","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2023.41.16_suppl.8013","article-title":"Impact of bridging therapy (BT) on outcome of relapsed refractory multiple myeloma (RRMM) with Ide-cel CAR T-cell therapy: real-world experience from the US myeloma CAR T consortium","volume":"41","author":"Hashmi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2\u20133","key":"10.1016\/j.clml.2024.01.014_bib0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s44228-023-00037-7","article-title":"Safety of CAR-T cell therapy in patients with renal failure\/acute kidney injury: focused review","volume":"5","author":"Khan","year":"2023","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.clml.2024.01.014_bib0056","unstructured":"Prescribing Information. Cyclophosphamide. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012141s090,012142s112lbl.pdf. 2023. Accessed: January 15, 2024."},{"key":"10.1016\/j.clml.2024.01.014_bib0057","unstructured":"Prescribing Information. Fludara. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020038s032lbl.pdf. 2008. Accessed: January 15, 2024."},{"issue":"35","key":"10.1016\/j.clml.2024.01.014_bib0058","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.01.014_bib0059","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0060","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2024.01.014_bib0061","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.clml.2024.01.014_bib0062","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtct.2023.03.021","article-title":"Bridging the gap: early transition and hybrid models of care to improve access to chimeric antigen receptor T cell therapy","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.clml.2024.01.014_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2024.01.014_bib0064","first-page":"1","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","volume":"40","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"10.1016\/j.clml.2024.01.014_bib0065","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.01.014_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1016\/j.clml.2024.01.014_bib0067","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clml.2024.01.014_bib0068","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.01.014_bib0069","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T02:28:31Z","timestamp":1713925711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2152265024000582"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}